Carfilzomib

Back to search

Molecule Structure

Scientific Name

Carfilzomib

Description of the Drug

Carfilzomib is a proteasome inhibitor used either alone or in conjunction with a chemotherapy regimen to treat patients with relapsed or refractory multiple myeloma.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB08889

Brand Name(s)

Kyprolis

Company Owner(s)

Apotex Inc, Dr Reddys Laboratories Ltd, Onyx Therapeutics Inc A Wholly Owned Sub Of Amgen Inc, Breckenridge Pharmaceutical Inc

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
26S proteasome PROTEIN COMPLEX INHIBITOR CHEMBL2364701

Unichem Links

SureChEMBL SCHEMBL85165
PharmGKB PA166165203
DrugBank DB08889
PubChem: Thomson Pharma 16812122 16658822
PubChem 11556711
LINCS LSM-45547
Nikkaji J2.711.864J
BindingDB 50277889
EPA CompTox Dashboard DTXSID4048690
DrugCentral 4483
Brenda 83670
ChemicalBook CB12520831
Guide to Pharmacology 7420
rxnorm KYPROLIS CARFILZOMIB
PubChem: Drugs of the Future 92309411
ChEBI 65347
ZINC ZINC000049841054